Natera

Natera EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Natera (NTRA) as of Nov 1, 2026 is 127.94. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 203.72 — a change of -37.20% (lower).

EV/OCF

127.94

YoY

-37.20%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Natera is 2025 127.94 . EV/OCF (Enterprise Value to Operating Cash Flow) of Natera was 2024 203.72 . It decreases by -37.20% lower compared to the previous year.

The Natera EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-403.73 USD
Jan 1, 2019
-444.62 USD
Jan 1, 2020
-153.64 USD
Jan 1, 2021
-83.35 USD
Jan 1, 2022
-64.87 USD
Jan 1, 2023
-113.42 USD
Jan 1, 2024
203.72 USD
Jan 1, 2025
127.94 USD
The Natera EV/OCF history
YEAREV/OCFYoY
127.94-37.20%
203.72-279.61%
-113.42+74.86%
-64.87-22.18%
-83.35-45.75%
-153.64-65.44%
-444.62+10.13%
-403.73+38.43%
-291.65-24.03%
-383.91-48.75%
-749.04-127.60%
2,713.59—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Natera Stock analysis

What does Natera do? Natera Inc. is an American company headquartered in San Carlos, California. It was founded in 2004 by Matthew Rabinowitz and has been listed on the NASDAQ under the ticker symbol "NTRA" since 2015. The company is a leading provider of diagnostic tests and analyses and specializes in genetic analysis and diagnostic technologies. Natera specializes in tests for various medical areas, particularly in oncology diagnostics. The company's vision is to improve the quality of life for millions of people worldwide by offering innovative diagnostic tests to detect diseases early and ensure optimal treatment. Natera offers a wide range of products tailored to the needs of consumers, physicians, and scientists. The company operates in three business areas: 1) Women's Health: Natera offers tests for women and couples to determine the risk of hereditary diseases. For example, the company offers a test that allows analysis of fetal DNA from the mother's blood, allowing detection of genetic abnormalities in the fetus before birth. Additionally, Natera offers the Panorama test, which provides tests for genetic anomalies in unborn babies that can be used to determine the risk for chromosomal abnormalities and genetic mutations. 2) Oncology: In the field of oncology, Natera offers a wide range of diagnostic tests targeting developments and trends in cancer research. The tests aim to enable accurate diagnosis and prognosis, as well as provide individualized treatment for each patient. The company offers tests that assess the current tumor growth and metastatic potential, enable determination of tumor burden in cells, and provide tests for specific mutations required for determining optimal treatment. 3) Genomic Analysis: In the field of genomic analysis, Natera offers a broad range of tests available to researchers and scientists. This includes genetic variants and biological mechanisms that cause diseases. The company is also committed to developing its tests through artificial intelligence (AI) and machine learning. The goal is to provide more accurate and faster results, improve clinical decisions, and advance research and development of new diagnostics. Conclusion: Natera is a leading company in the field of diagnostic tests and analyses in the field of genomic analysis. The company has a long history of research and development of innovative product solutions for the medical community. One important focus of the company is to improve women's health and be able to detect risks for genetic diseases early; the other focus is on oncology diagnostic tools to determine optimal treatment for cancer patients. The company is constantly striving to further develop its tests and integrate new research findings and technologies to support the medical science community. Natera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natera stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Natera is 127.94 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Natera changed from 203.72 to 127.94, representing a -37.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Natera since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Natera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Natera

All Key Metrics — Natera